Indication

Polymyositis-associated Interstitial Lung Disease

1 clinical trial

1 product

1 drug

Clinical trial

Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19

Status: Completed, Estimated PCD: 2023-12-31

Product

Drug